Rep. Gilbert Ray Cisneros, Jr. Sells Veracyte, Inc. (NASDAQ:VCYT) Stock

Representative Gilbert Ray Cisneros, Jr. (D-California) recently sold shares of Veracyte, Inc. (NASDAQ:VCYT). In a filing disclosed on December 15th, the Representative disclosed that they had sold between $1,001 and $15,000 in Veracyte stock on November 12th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Spotify Technology (NYSE:SPOT) on 11/26/2025.
• Sold $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOGL) on 11/26/2025.
• Purchased $1,001 – $15,000 in shares of First Watch Restaurant Group (NASDAQ:FWRG) on 11/26/2025.
• Purchased $1,001 – $15,000 in shares of TKO Group (NYSE:TKO) on 11/26/2025.
• Sold $1,001 – $15,000 in shares of RBC Bearings (NYSE:RBC) on 11/24/2025.
• Sold $1,001 – $15,000 in shares of Stifel Financial (NYSE:SF) on 11/24/2025.
• Purchased $1,001 – $15,000 in shares of Logan Energy (CVE:LGN) on 11/24/2025.
• Sold $1,001 – $15,000 in shares of Primoris Services (NASDAQ:PRIM) on 11/24/2025.
• Purchased $15,001 – $50,000 in shares of LandBridge (NYSE:LB) on 11/21/2025.
• Purchased $50,001 – $100,000 in shares of LandBridge (NYSE:LB) on 11/20/2025.

Veracyte Trading Up 2.1%

VCYT stock traded up $0.88 during mid-day trading on Friday, hitting $42.92. 1,159,960 shares of the company were exchanged, compared to its average volume of 903,586. The business has a 50 day simple moving average of $40.91 and a 200-day simple moving average of $33.07. The stock has a market capitalization of $3.39 billion, a PE ratio of 112.95 and a beta of 1.83. Veracyte, Inc. has a 1-year low of $22.61 and a 1-year high of $50.71.

Veracyte (NASDAQ:VCYT) last posted its earnings results on Tuesday, November 4th. The biotechnology company reported $0.51 EPS for the quarter, beating the consensus estimate of $0.32 by $0.19. The company had revenue of $131.87 million for the quarter, compared to the consensus estimate of $124.62 million. Veracyte had a return on equity of 7.23% and a net margin of 6.12%.The firm’s revenue for the quarter was up 13.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.33 earnings per share. Equities research analysts expect that Veracyte, Inc. will post 0.68 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on VCYT. Zacks Research raised Veracyte from a “hold” rating to a “strong-buy” rating in a report on Monday, October 6th. Morgan Stanley boosted their price objective on shares of Veracyte from $40.00 to $48.00 and gave the company an “underweight” rating in a report on Monday, December 1st. Needham & Company LLC raised their target price on shares of Veracyte from $41.00 to $44.00 and gave the stock a “buy” rating in a report on Wednesday, November 5th. Guggenheim boosted their price target on Veracyte from $40.00 to $45.00 and gave the company a “buy” rating in a research note on Wednesday, November 5th. Finally, UBS Group increased their price target on Veracyte from $42.00 to $48.00 and gave the stock a “buy” rating in a research report on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $45.43.

Institutional Trading of Veracyte

Institutional investors and hedge funds have recently modified their holdings of the business. BNP PARIBAS ASSET MANAGEMENT Holding S.A. bought a new position in Veracyte in the second quarter valued at about $25,000. First Horizon Corp bought a new stake in shares of Veracyte during the 3rd quarter valued at approximately $31,000. Osaic Holdings Inc. increased its position in Veracyte by 289.9% during the 2nd quarter. Osaic Holdings Inc. now owns 1,201 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 893 shares in the last quarter. Neo Ivy Capital Management bought a new position in Veracyte in the 3rd quarter valued at approximately $56,000. Finally, Headlands Technologies LLC boosted its position in Veracyte by 74.8% in the second quarter. Headlands Technologies LLC now owns 2,824 shares of the biotechnology company’s stock valued at $76,000 after buying an additional 1,208 shares in the last quarter.

Insider Activity

In related news, insider John Leite sold 1,278 shares of the firm’s stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $47.51, for a total value of $60,717.78. Following the completion of the transaction, the insider owned 82,113 shares in the company, valued at $3,901,188.63. This trade represents a 1.53% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Marc Stapley sold 7,668 shares of the business’s stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average price of $47.09, for a total transaction of $361,086.12. Following the sale, the chief executive officer directly owned 318,603 shares in the company, valued at $15,003,015.27. The trade was a 2.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 142,984 shares of company stock valued at $6,282,692. 1.40% of the stock is currently owned by insiders.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Veracyte

Veracyte, Inc is a genomic diagnostics company focused on improving diagnostic accuracy and patient care through advanced molecular testing. Founded in 2008 and headquartered in South San Francisco, California, the company develops and commercializes minimally invasive genomic tests that aid in the diagnosis of thyroid, lung and other diseases. Veracyte’s proprietary platform analyzes gene expression patterns in clinical samples to help physicians make more informed treatment decisions, reducing unnecessary surgeries and improving patient outcomes.

The company’s flagship product, the Afirma Genomic Sequencing Classifier, is designed to assess thyroid nodules with indeterminate cytology, helping clinicians distinguish benign from suspicious nodules.